A novel A33 promoter-based conditionally replicative adenovirus suppresses tumor growth and eradicates hepatic metastases in human colon cancer models

Clinical Cancer Research

Volumn 15, Issue 9, 2009, Pages 3037-3049

  Cafferata, Eduardo G ^a   Macció, Daniela R ^a   Lopez, Maria V ^a   Viale, Diego L ^a   Carbone, Cecilia ^c   Mazzolini, Guillermo ^b   Podhajcer, Osvaldo L ^a  

^a FUNDACIÓN INSTITUTO LELOIR   (Argentina)

^b UNIVERSIDAD AUSTRAL   (Argentina)

^c FACULTAD DE CIENCIAS VETERINARIAS   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; AV22EL; FLUOROURACIL; MEMBRANE PROTEIN; PROTEIN A33; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER METASTASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; VIRUS RECOMBINANT;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BETA-GALACTOSIDASE; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA, HEPATOCELLULAR; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FETUS; FIBROBLASTS; FLUOROURACIL; GENETIC VECTORS; HUMANS; LIVER NEOPLASMS; LUCIFERASES; LUNG; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPHEROIDS, CELLULAR; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 65649142589     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1161     Document Type: Article

References (50)

1. Elias D, Liberale G, Vernerey D, et al. Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol 2005;12: 900-909
2. Lorenz M, Staib-Sebler E, Hochmuth K, et al. Surgical resection of liver metastases of colorectal carcinoma: short and long-term results. Semin Oncol 2000; 27:112-119
3. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005;352:476-487
4. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interimresults of a phase III trial. J Clin Oncol 2003;21:2059-2069 (Pubitemid 46606353)
5. Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997;15:251-260
6. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407-1412
7. Post DE, Van Meir EG. A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. Oncogene 2003;22:2065-2072 (Pubitemid 36539557)
8. Yu DC, Working P, Ando D. Selectively replicating oncolytic adenoviruses as cancer therapeutics. Curr Opin Mol Ther 2002;4:435-443 (Pubitemid 36305035)
9. Bauerschmitz GJ, Guse K, Kanerva A, et al. Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells. Mol Ther 2006;14:164-174
10. Li Y, Chen Y, Dilley J, et al. Carcinoembryonic antigen-producing cell-specific oncolytic adenovirus, OV798, for colorectal cancer therapy. Mol Cancer Ther 2003;2:1003-1009
11. Dabrowska A, Szary J, Kowalczuk M, Szala S, Ugorski M. CEA-negative glioblastoma and melanoma cells are sensitive to cytosine deaminase/5- fluorocytosine therapy directed by the carcinoembryonic antigen promoter. Acta Biochim Pol 2004;51:723-732
12. Qiao J, Doubrovin M, Sauter BV, et al. Tumor-specific transcriptional targeting of suicide gene therapy. Gene Ther 2002;9:168-175
13. Yamamoto M, Davydova J, Wang M, et al. Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology 2003;125:1203-1218
14. Irving J, Wang Z, Powell S, et al. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. Cancer Gene Ther 2004;11: 174-185
15. Shirakawa T, Hamada K, Zhang Z, et al. A cox-2 promoter-based replication-selective adenoviral vector to target the cox-2-expressing human bladder cancer cells. Clin Cancer Res 2004;10:4342-4348
16. Homicsko K, Lukashev A, Iggo RD. RAD001 (everolimus) improves the efficacy of replicating adenoviruses that target colon cancer. Cancer Res 2005;65: 6882-6890 (Pubitemid 41060727)
17. Lu ZZ, Ni F, Hu ZB, et al. Efficient gene transfer into hematopoietic cells by a retargeting adenoviral vector system with a chimeric fiber of adenovirus serotype 5 and11p. Exp Hematol 2006;34:1171-1182
18. Stoff A, Rivera AA, Banerjee NS, et al. Strategies to enhance transductional efficiency of adenoviral-based gene transfer to primary human fibroblasts and keratinocytes as a platform in dermal wounds. Wound Repair Regen 2006;14:608-617
19. Heath JK, White SJ, Johnstone CN, et al. The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily. Proc Natl Acad Sci U S A 1997;94:469-474
20. Sakamoto J, Kojima H, Kato J, Hamashima H, Suzuki H. Organ-specific expression of the intestinal epithelium-related antigen A33, a cell surface target for antibody-based imaging and treatment in gastrointestinal cancer. Cancer Chemother Pharmacol 2000; 46 Suppl:S27-32.
21. Moss A, Doran P, MacMathuna P. In silico promoter analysis can predict genes of functional relevance in cell proliferation: validation in a colon cancer model. Translational Oncogenomics 2007;2:1-16.
22. Almqvist Y, Steffen AC, Lundqvist H, Jensen H, Tolmachev V, Sundin A. Biodistribution of 211At-labeled humanized monoclonal antibody A33. Cancer Biother Radiopharm 2007;22:480-487 (Pubitemid 47403468)
23. King DJ, Antoniw P, Owens RJ, et al. Preparation and preclinical evaluation of humanised A33 immuno-conjugates for radioimmunotherapy. Br J Cancer 1995; 72:1364-1372
24. Scott AM, Lee FT, Jones R, et al. A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake. Clin Cancer Res 2005;11:4810-4817
25. Welt S, Divgi CR, Real FX, et al. Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33. J Clin Oncol 1990;8:1894-1906
26. Welt S, Ritter G, Williams C Jr, et al. Phase I study of anticolon cancer humanized antibody A33. Clin Cancer Res 2003;9:1338-1346
27. Kanerva A, Hemminki A. Adenoviruses for treatment of cancer. Ann Med 2005;37:33-43. (Pubitemid 40342423)
28. Jakubczak JL, Ryan P, Gorziglia M, et al. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy. Cancer Res 2003;63: 1490-1499
29. Martin-Duque P, Jezzard S, Kaftansis L, Vassaux G. Direct comparison of the insulating properties of two genetic elements in an adenoviral vector containing two different expression cassettes. Hum Gene Ther 2004;15:995-1002. (Pubitemid 39372576)
30. Bett AJ, Haddara W, Prevec L, Graham FL. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci U S A 1994;91:8802-8806
31. Lieber A, He CY, Kirillova I, Kay MA. Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo. J Virol 1996;70:8944-8960 (Pubitemid 26378479)
32. Tang DC, Johnston SA, Carbone DP. Butyrateinducible and tumor-restricted gene expression by adenovirus vectors. Cancer GeneTher 1994;1:15-20.
33. Vondran FW, Katenz E, Schwartlander R, et al. Isolation of primary human hepatocytes after partial hepatectomy: criteria for identification of the most promising liver specimen. Artif Organs 2008;32: 205-213
34. Lopez MV, Blanco P, Viale DL, et al. Expression of a suicidal gene under control of the human secreted protein acidic and rich in cysteine (SPARC) promoter in tumor or stromal cells led to the inhibition of tumor cell growth. Mol Cancer Ther 2006;5:2503-2511
35. Li Y, Yu DC, Chen Y, et al. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res 2001;61:6428-6436
36. Bazan-Peregrino M, Carlisle RC, Hernandez-Alcoceba R, et al. Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus. Hum Gene Ther 2008;19:873-886
37. Bazan-Peregrino M, Carlisle RC, Purdie L, Seymour LW. Factors influencing retention of adenovirus within tumours following direct intratumoural injection. Gene Ther 2008;15:688-694
38. Hoffmann D, Wildner O. Efficient generation of double heterologous promoter controlled oncolytic adenovirus vectors by a single homologous recombination step in Escherichia coli. BMC Biotechnol 2006;6:36. (Pubitemid 44314520)
39. Sova P, Ren XW, Ni S, et al. A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Mol Ther 2004;9:496-509.
40. McGrory WJ, Bautista DS, Graham FL. A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology 1988; 163:614-617 (Pubitemid 18115467)
41. Zhang X, Bellett AJ, Hla RT, Voss T, Mullbacher A, Braithwaite AW. Down-regulation of human adenovirus E1a by E3 gene products: evidence for translational control of E1a by E3 14.5K and/or E3 10.4K products. J Gen Virol 1994;75:1943-1951. (Pubitemid 24243074)
42. Danielsson A, Dzojic H, Nilsson B, Essand M. Increased therapeutic efficacy of the prostate-specific oncolytic adenovirus Ad(I/PPT-E1A) by reduction of the insulator size and introduction of the full-length E3 region. Cancer Gene Ther 2008;15:203-213
43. Shashkova EV, Kuppuswamy MN, Wold WS, Doronin K. Anticancer activity of oncolytic adenovirus vector armed with IFN-α and ADP is enhanced by pharmacologically controlled expression of TRAIL. Cancer Gene Ther 2008;15:61-72.
44. Yun CO, Kim E, Koo T, Kim H, Lee YS, Kim JH. ADP-overexpressing adenovirus elicits enhanced cytopathic effect by induction of apoptosis. Cancer Gene Ther 2005;12:61-71. (Pubitemid 39665244)
45. Petersen S, Thames HD, Nieder C, Petersen C, Baumann M. The results of colorectal cancer treatment by p53 status: treatment-specific overview. Dis Colon Rectum 2001;44:322-33; discussion 333-334 (Pubitemid 32226320)
46. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH. ONYX-015, an E1B gene-attenuated adenovirus, causes tumorspecific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997;3:639-645 (Pubitemid 27264973)
47. Au T, Thorne S, Korn WM, Sze D, Kirn D, Reid TR. Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver. Cancer GeneTher 2007;14:139-150 (Pubitemid 46106958)
48. Wulff H, Krieger T, Kruger K, et al. Cloning and characterization of an adenoviral vector for highly efficient and doxycycline-suppressible expression of bioactive human single-chain interleukin 12 in colon cancer. BMC Biotechnol 2007;7:35.
49. Ritter G, Cohen LS, Williams C, Jr. Richards EC, Old LJ, Welt S. Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. Cancer Res 2001;61: 6851-6859 (Pubitemid 32896510)
50. Welt S, Ritter G, Williams C Jr, et al. Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer. Clin Cancer Res 2003;9:1347-1353